ArticleLiver cancer2025
No More Detours: Hepatopulmonary Shunt Reduction in a Patient with Hepatocellular Carcinoma after Treatment with Bevacizumab.
Article in Liver cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Treatment options for intermediate-stage hepatocellular carcinoma (HCC) include transarterial radioembolization (TARE) and systemic treatment. Currently, in the absence of contraindications, first-line systemic therapies include combinations of immune checkpoint inhibitors with anti-angiogenic agents or different checkpoint inhibitors. Combinations of TARE and systemic treatment are being investigated for synergistic effects due to a boosting of the immune response. However, a high hepatopulmonary shunt (HPS) fraction - abnormal passage of blood from the hepatic vasculature to the pulmonary circulation resulting from the formation of abnormal vasculature within the tumor - precludes some patients from receiving TARE due to the risk of nontarget lung radiation. Here, we present a case in which treatment of a patient with atezolizumab and bevacizumab led to a significant reduction in HPS, enabling locoregional treatment of the tumor while the tumor did not respond to systemic treatment alone according to the mRECIST criteria. Case Presentation: Here, we report the case of a patient with intermediate-stage HCC who received systemic treatment with atezolizumab and bevacizumab due to a high HPS fraction of 42% precluding him from treatment with radioembolization. Despite eventually showing tumor progression to systemic treatment based on clinical and radiological evaluation, the lung shunt fraction was markedly reduced by the systemic treatment to only 3.4%, enabling successful treatment of the tumor with radioembolization. Conclusion: The anti-angiogenic effects of bevacizumab may reduce HPS in patients with intermediate-stage HCC, thereby extending the utility of TARE. In patients who do not respond to systemic treatment and who are amenable to treatment with TARE due to tumor stage, repeated measurements of HPSF might be considered after treatment with bevacizumab.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.